MedTrace Logo

VEN+IDAC vs IDAC in AML

NCT07537257 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2026-04-17

No results posted yet for this study

Summary

This study intends to use a randomized controlled design to compare the MRD-negativw rate and related efficacy and safety of venetoclax combined with intermediate-dose cytarabine (IDAC) versus IDAC in the consolidation treatment of patients with AML after remission, providing high-quality evidence-based medical evidence for optimizing post-remission consolidation therapy for AML and improving patients' prognosis.

Conditions

  • AML (Acute Myelogenous Leukemia)

Interventions

DRUG

Ventoclax

Venetoclax 400mg per day from day 1 to day 7

DRUG

Cytarabine

Cytarabine 1.5g/m\^2 q12h from day 1 to day 3.

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER

  • First Affiliated Hospital of Guangxi Medical University

    collaborator OTHER

  • Guangzhou First People's Hospital

    collaborator OTHER

  • Dongguan People's Hospital

    collaborator OTHER_GOV

  • Zhongshan People's Hospital, Guangdong, China

    collaborator OTHER

  • Shunde Hospital, Sothen Medical University

    collaborator UNKNOWN

  • Shenzhen Second People's Hospital

    collaborator OTHER

  • Guangdong Second Provincial General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2027-04-01
Completion
2029-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07537257 on ClinicalTrials.gov